Validation and characterization of antibody responses to Plasmodium falciparum antigens identified by protein array screening
通过蛋白质阵列筛选鉴定的针对恶性疟原虫抗原的抗体反应的验证和表征
基本信息
- 批准号:10195524
- 负责人:
- 金额:$ 7.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-10 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAffectAfricanAntibodiesAntibody ResponseAntigen TargetingAntigenic DiversityAntigensAntiparasitic AgentsAreaBiological AssayBloodCaspaseCessation of lifeChildClinicalClinical TrialsCohort StudiesCommunity DevelopmentsComplementConflict (Psychology)DiseaseEpidemicErythrocytesEvaluationExhibitsExposure toFalciparum MalariaFeverFundingGenerationsGenesGenetic VariationGoalsGrowthImmunityImmunizationImmunizeImmunoglobulin GImmunologic FactorsIn VitroIndividualInfantInfectionLengthLiverLongitudinal cohortLongitudinal cohort studyMalariaMalaria VaccinesMaliMeasuresNatural DisastersOryctolagus cuniculusParasitemiaParasitesParentsParticipantPlasmodium falciparumPoliticsPopulationProspective StudiesProspective cohort studyProtein ArrayProtein MicrochipsProtein RegionProteinsRecombinant ProteinsRecombinantsRiskSerumSporozoitesSterilitySystemTestingVaccinesValidationVirusacquired immunityasexualbasecircumsporozoite proteincohortdesignhealth care deliveryimmunogenicityimprovedin vitro activityinsightpre-clinical assessmentpreventprospectiveprotein expressionresponsescreeningtoolvaccine candidatevaccine developmentvaccine efficacyvector control
项目摘要
PROJECT SUMMARY
Malaria afflicts more than 200 million people yearly, with the malaria parasite Plasmodium falciparum being
responsible for the vast majority of the ~405,000 malaria deaths in 2018. A highly effective malaria vaccine is
widely viewed as a much-needed tool for reducing malaria in endemic areas where healthcare delivery and
vector control strategies are often disrupted by political conflict, natural disasters, and epidemics of rapidly
transmissible viruses. Vaccines that target pre-erythrocytic antigens and whole sporozoite immunization
approaches aim to induce sterile immunity that prevents the progression of liver-stage infection and thus the
establishment of parasitemia and clinical malaria. However, the first licensed malaria vaccine, which targets the
pre-erythrocytic circumsporozoite protein, is only partially effective at preventing severe malaria in African
infants. Inclusion of asexual blood-stage antigens in a multi-stage malaria vaccine could improve the efficacy of
partially effective first-generation vaccines by mitigating clinical disease caused by breakthrough parasitemia.
Several promising blood-stage antigens have been prioritized in clinical trials, but the continued evaluation of
other antigens in the malaria vaccine development pipeline is prudent given the challenges of achieving field
efficacy against a genetically diverse parasite. In our preliminary studies, we found that antibody responses
against two distinct P. falciparum antigens were significantly increased in a subset of malaria-protected children
relative to malaria-susceptible children in a longitudinal cohort study conducted in Mali. We propose to evaluate
these two P. falciparum antigens as malaria vaccine candidates by determining whether naturally acquired IgG
antibodies against these proteins can predict malaria protection in the larger parent cohort and exert anti-
parasitic activity. Our hypothesis is that conserved regions within either antigen are the targets of naturally
acquired protective immunity against falciparum malaria. To test this hypothesis, we will determine the genetic
diversity of local P. falciparum field isolates within the genes encoding these parasite antigens, which will allow
us to identify a conserved region for recombinant protein expression. We will then determine if naturally acquired
antibody responses against the conserved region within each antigen can predict protection from malaria in the
parent cohort study and whether these antibodies have activity against P. falciparum parasites in vitro.
Successful completion of this project will provide insight on the genetic diversity of these two antigens and
provide evidence as to whether conserved regions within these antigens are the targets of naturally acquired
protective immunity against malaria.
项目总结
疟疾每年折磨着2亿多人,其中疟疾寄生虫恶性疟原虫是
2018年约40.5万人死于疟疾,其中绝大多数是罪魁祸首。一种高效的疟疾疫苗是
被广泛视为在流行地区减少疟疾的迫切需要的工具,在那里提供医疗保健和
病媒控制战略经常受到政治冲突、自然灾害和迅速流行的疾病的干扰。
可传播的病毒。针对红细胞前抗原和全子孢子免疫的疫苗
方法的目的是诱导无菌免疫,以防止肝期感染的进展,从而
建立寄生虫血症和临床疟疾。然而,第一种获得许可的疟疾疫苗,针对的是
红细胞前环子孢子蛋白在预防非洲严重疟疾方面只有部分效果
婴儿。在多阶段疟疾疫苗中加入无性血液期抗原可以提高疟疾疫苗的效力
通过减轻突破性寄生虫血症引起的临床疾病,第一代疫苗部分有效。
几种有希望的血液阶段抗原已经在临床试验中被优先考虑,但对
考虑到实现实地研究的挑战,疟疾疫苗开发流程中的其他抗原是谨慎的
对一种遗传多样性寄生虫的疗效。在我们的初步研究中,我们发现抗体反应
抗两种不同恶性疟原虫的抗原在一组受疟疾保护的儿童中显著增加
在马里进行的一项纵向队列研究中,与易患疟疾的儿童有关。我们建议评估
通过测定这两种恶性疟原虫抗原作为疟疾疫苗候选疫苗的天然获得性免疫球蛋白
针对这些蛋白的抗体可以预测疟疾在较大的父母队列中的保护作用,并对
寄生活动。我们的假设是,这两种抗原中的保守区域都是天然
获得对恶性疟疾的保护性免疫。为了检验这一假设,我们将确定基因
在编码这些寄生虫抗原的基因内,当地恶性疟原虫田间分离株的多样性,这将使
US以确定重组蛋白表达的保守区。然后我们将确定自然获得的
针对每个抗原内保守区的抗体反应可以预测对疟疾的保护作用
亲代队列研究以及这些抗体是否具有体外抗恶性疟原虫活性。
该项目的成功完成将为了解这两种抗原的遗传多样性和
提供证据证明这些抗原中的保守区是否是自然获得性
对疟疾的保护性免疫。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tuan Manh Tran其他文献
Tuan Manh Tran的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tuan Manh Tran', 18)}}的其他基金
Validation and characterization of antibody responses to Plasmodium falciparum antigens identified by protein array screening
通过蛋白质阵列筛选鉴定的针对恶性疟原虫抗原的抗体反应的验证和表征
- 批准号:
10348213 - 财政年份:2021
- 资助金额:
$ 7.93万 - 项目类别:
Evaluating the role of P53 pathways in malaria
评估 P53 通路在疟疾中的作用
- 批准号:
10184664 - 财政年份:2021
- 资助金额:
$ 7.93万 - 项目类别:
Investigating gene regulatory networks in immune cells of children who differ in susceptibility to malaria infection using single-cell approaches
使用单细胞方法研究对疟疾感染易感性不同的儿童免疫细胞中的基因调控网络
- 批准号:
10323061 - 财政年份:2021
- 资助金额:
$ 7.93万 - 项目类别:
Evaluating the role of P53 pathways in malaria
评估 P53 通路在疟疾中的作用
- 批准号:
10543821 - 财政年份:2021
- 资助金额:
$ 7.93万 - 项目类别:
Defining clinical and sterile immunity to Plasmodium falciparum infection using systems biology approaches
使用系统生物学方法定义针对恶性疟原虫感染的临床和无菌免疫
- 批准号:
9427961 - 财政年份:2017
- 资助金额:
$ 7.93万 - 项目类别:
Defining clinical and sterile immunity to Plasmodium falciparum infection using systems biology approaches
使用系统生物学方法定义针对恶性疟原虫感染的临床和无菌免疫
- 批准号:
10097958 - 财政年份:2017
- 资助金额:
$ 7.93万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 7.93万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 7.93万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 7.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 7.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 7.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)